ZURICH-SCHLIEREN, Switzerland, Molecular Partners AG, a pioneer in the development of a novel class of therapeutic compounds (DARPins), has announced the closing of its Series A equity investment round raising 18.5 Mio CHF (??.28 million, $15.56 million). The round was led by Index Ventures (Geneva, Jersey, London), a leading venture capital firm that has been very active in the antibody space, and was further supported by an international syndicate of investors, representing the US and Europe, including BB Biotech Ventures (Zurich), Johnson & Johnson Development Corporation (US) and Endeavour (Geneva).
